We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+2.97%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.74B
AUM Growth
+$71.7M
Cap. Flow
+$132M
Cap. Flow %
7.63%
Top 10 Hldgs %
59.59%
Holding
81
New
17
Increased
17
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$85.8M
2
VERA icon
Vera Therapeutics
VERA
+$45.3M
3
BIIB icon
Biogen
BIIB
+$33.5M
4
HRTX icon
Heron Therapeutics
HRTX
+$23.3M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$22.6M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$42.1M
2
LLY icon
Eli Lilly
LLY
+$33.7M
3
MRUS
Merus
MRUS
+$27.4M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$17.9M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKUS
26
DELISTED
Akouos Inc
AKUS
$19M 1.1%
1,515,074
– –
PODD icon
27
Insulet
PODD
$11.3B
$18.8M 1.08%
68,500
+51,000
+291% +$13.9M
VRTX icon
28
Vertex Pharmaceuticals
VRTX
$121B
$17.8M 1.03%
88,214
+42,514
+93% +$8.89M
RGNX icon
29
Regenxbio
RGNX
$623M
$16.6M 0.96%
427,740
+66,005
+18% +$2.36M
NCNA
30
NuCana
NCNA
$5.37M
$15.5M 0.89%
1,120
– –
AGEN
31
Agenus
AGEN
$249M
$15.2M 0.88%
141,126
-36,088
-20% -$2.71M
DXCM icon
32
DexCom
DXCM
$27.6B
$14.4M 0.83%
134,852
+26,852
+25% +$2.58M
OBSV
33
DELISTED
ObsEva SA Ordinary Shares
OBSV
$14.4M 0.83%
4,749,623
– –
ITCI
34
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.8M 0.74%
313,159
-341,842
-52% -$12.6M
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.7M 0.73%
78,538
-59,492
-43% -$9.55M
AGIO icon
36
Agios Pharmaceuticals
AGIO
$2.16B
$12.1M 0.7%
+219,033
New +$12.2M
RETA
37
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11.3M 0.65%
79,601
-158,919
-67% -$17.9M
QURE icon
38
uniQure
QURE
$2.68B
$9.99M 0.58%
324,303
-102,819
-24% -$3.45M
AMGN icon
39
Amgen
AMGN
$203B
$9.87M 0.57%
40,500
+1,632
+4% +$401K
CYTK icon
40
Cytokinetics
CYTK
$11B
$9.53M 0.55%
481,323
+91,603
+24% +$2.15M
KURA icon
41
Kura Oncology
KURA
$922M
$9.27M 0.53%
444,372
+361,208
+434% +$8.97M
MGNX icon
42
MacroGenics
MGNX
$235M
$6.3M 0.36%
234,504
+161,303
+220% +$4.72M
CCXI
43
DELISTED
ChemoCentryx, Inc.
CCXI
$6.24M 0.36%
465,637
+285,638
+159% +$7.04M
MRNS
44
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$6.21M 0.36%
346,160
-24,191
-7% -$389K
CHRS icon
45
Coherus Oncology
CHRS
$217M
$6.01M 0.35%
434,555
– –
CYT
46
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$5.67M 0.33%
+265,000
New +$4.96M
KYNB
47
PUT
Kyntra Bio
KYNB
$28.5M
$5.33M 0.31%
+8,000
New +$4.61M
IMTX icon
48
Immatics
IMTX
$1.24B
$5.15M 0.3%
443,370
+58,271
+15% +$684K
AMRN
49
Amarin Corp
AMRN
$284M
$5.13M 0.3%
58,529
– –
TCRR
50
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$4.86M 0.28%
296,282
-40,400
-12% -$816K
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2021 Portfolio in Review

As of Q2 2021, Sofinnova Investments held 81 positions worth $1.74B, up 4.3% from $1.66B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $132M of net new capital in Q2 2021, opening 17 new positions and adding to 17 existing holdings. Its largest new stake was Jade Biosciences: 107,391 shares worth $85.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $17.9M trimmed.

  • Sofinnova Investments's largest Q2 2021 buy was Jade Biosciences: 107,391 shares worth $85.8M.
  • Sofinnova Investments added most to Insulet in Q2 2021, an estimated $13.9M increase.
  • Sofinnova Investments's biggest Q2 2021 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $17.9M.
  • Sofinnova Investments fully exited Jazz Pharmaceuticals in Q2 2021, selling an estimated $42.1M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.74B portfolio in Q2 2021.
  • Sofinnova Investments opened 17 new positions and closed 14 in Q2 2021.
  • Sofinnova Investments's portfolio value rose 4.3% quarter-over-quarter to $1.74B.

Based on Sofinnova Investments's 13F filing for Q2 2021, filed 16 Aug 2021.